Biologics for evaluating drug targets: an interview with Michael Schwenkert

In this interview, Michael Schwenkert (Bio-Rad Laboratories; CA, USA) discusses the use of neo-epitope specific antibodies in the field of drug discovery and development.

Go to the profile of MedChemNet
Feb 08, 2018
0
0
Upvote 0 Comment

In this interview, Michael Schwenkert (Bio-Rad) talks to Bioanalysis Zone about the poster he presented at EBF 2017 (Barcelona, Spain).  Learn more about the use of antibodies to evaluate drug targets and the development of neo-epitope specific antibodies at Bio-Rad.

Did you enjoy this interview? You may also like:
Go to the profile of MedChemNet

MedChemNet

A network for the medicinal chemistry community, Future Science Group

Your source for the latest news and views from the fields of drug discovery and medicinal chemistry.

No comments yet.